Company Description
TRex Bio is a clinical-stage biopharmaceutical company focused on tissue Treg biology for the discovery and development of immunoregulatory medicines designed to restore immune balance and promote tissue repair to address unmet needs of patients with autoimmune and inflammatory diseases.
TRexBio was built on a pivotal scientific insight: that regulatory T cells (“Tregs”) in human tissue are not merely passive suppressors of inflammation, but active orchestrators of tissue immune homeostasis and repair.
Our most advanced wholly-owned product candidate, TRB-061, is an investigational tumor necrosis factor receptor 2 (“TNFR2”) agonist designed to expand and activate Tregs in inflamed tissues.
We believe TRB-061 has broad, multi-indication potential, and are currently conducting a Phase 1a/b clinical trial of TRB-061 in healthy volunteers and patients with moderate-to-severe atopic dermatitis.
We expect to announce topline data from the Phase 1b portion of the TRB-061 trial in mid-2027.
| Country | United States |
| Founded | 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 60 |
| CEO | M. Johnston Erwin, Jr. |
Contact Details
Address: 269 East Grand Avenue, Suite 300 South San Francisco, CA 94080 United States | |
| Phone | (650) 567-5582 |
| Website | trex.bio |
Stock Details
| Ticker Symbol | TRXB |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 2139097 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| M. Johnston Erwin, Jr. | Chief Executive Officer and Chair |
| Laura Berner | Chief Operating Officer |
| Brandon Hants | Chief Financial Officer |
| Ariella Kelman | Chief Medical Officer |
| Ali Zarrin | Chief Scientific Officer |
| Carol G. Gallagher | Director and Lead Independent Director |
| Alexandra Cantley | Director |
| Travis Coy | Director |
| Julie Gilmore | Director |
| Peter Hirth | Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 18, 2026 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Aug 21, 2026 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| Jul 31, 2026 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| Jun 26, 2026 | DRS | [Cover] Draft Registration Statement |